A peptide for arousal and libido that works differently from the hormone-based approaches.
Sexual wellness is one of the less openly discussed areas of clinical care, but one where many women have meaningful concerns. PT-141, also known as bremelanotide, is a peptide that has shown utility for arousal disorders in women, working through a fundamentally different mechanism than hormone-based approaches.
How it works. PT-141 acts on melanocortin receptors in the central nervous system. The receptors are involved in regulating sexual arousal pathways. Unlike testosterone or other hormonal approaches, PT-141 does not change baseline hormone levels, it works on a more immediate, on-demand basis.
Who it can help. Women experiencing hypoactive sexual desire disorder, defined as persistent low desire that causes distress and is not explained by other medical or relationship factors. Women on certain medications (notably SSRIs) that have reduced libido as a side effect. Postmenopausal women where lifestyle and topical approaches have not addressed the concern.
How it is delivered. PT-141 is administered as a subcutaneous injection, taken before anticipated sexual activity. Onset is typically 30 to 60 minutes after the dose. Effects last several hours. It is not taken daily, it is used episodically.
What to expect. Most clients respond to a low starting dose. Side effects can include facial flushing, mild nausea on first doses (which usually fades with continued use), and occasionally headache. We start at the lowest effective dose and titrate up only if needed.
Who should not use it. Clients with uncontrolled high blood pressure, certain cardiovascular conditions, or melanoma history. We screen carefully. PT-141 has effects on blood pressure that we evaluate at consultation.
How we manage the conversation. With dignity and clinical care. The consultation includes a discussion of the wider picture, relationship factors, sleep, medications, hormone status, mental health, since arousal concerns are usually multifactorial. PT-141 is a tool within a broader conversation, not a substitute for it.
This is not a peptide we promote casually. It is appropriate for specific clinical situations and requires proper screening, follow-up, and an honest conversation about expectations.